


















1212Advancement of Pediatric Blood and Marrow
Transplantation Research in North America: Priorities
of the Pediatric Blood and Marrow Transplant
Consortium
Michael A. Pulsipher,1 Edwin M. Horwitz,2 Ann E. Haight,3 Richard Kadota,4 Allen R. Chen,5
Haydar Frangoul,6 Laurence J. N. Cooper,7 David A. Jacobsohn,8 Rakesh K. Goyal,9
David Mitchell,10 Michael L. Nieder,11 Gregory Yanik,12 Morton J. Cowan,13 Sandeep Soni,14
Sharon Gardner,15 Shalini Shenoy,16 Douglas Taylor,17 Mitchell Cairo,18 Kirk R. Schultz19Advances in pediatric bone marrow transplantation (BMT) are slowed by the small number of patients with
a given disease who undergo transplantation, a lack of sufficient infrastructure to run early-phase oncology
protocols and studies of rare nonmalignant disorders, and challenges associated with funding multi-institu-
tional trials. Leadership of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), a large pedi-
atric BMT clinical trials network representing 77 active and 45 affiliated centers worldwide, met in April 2009
to develop strategic plans to address these issues. Key barriers, including infrastructure development and
funding, along with scientific initiatives in malignant and nonmalignant disorders, cellular therapeutics,
graft-versus-host disease, and supportive care were discussed. The PBMTC’s agenda for approaching these
issues will result in infrastructure and trials specific to pediatrics that will run through the PBMTC or its part-
ners, the Blood and Marrow Transplant Clinical Trials Network and the Children’s Oncology Group.
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Table 1. Recent Pediatric BMT Trials Developed by PBMTC or Jointly by PBMTCWorking with Other Cooperative Groups
COG ASCT0431/PBMTC ONC051: A Randomized Trial of Sirolimus-Based Graft-versus-Host Disease Prophylaxis after Hematopoietic Stem Cell
Transplantation in Selected Patients with CR1 and CR2 ALL
COG ASCT0521/ PBMTC SUP051: Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Noninfectious Pulmonary
Dysfunction (Idiopathic Pneumonia Syndrome) following Allogeneic Stem Cell Transplantation
COG ASCT0631/PBMTC STC051: A Phase III Randomized Trial of G-CSF–Stimulated Bone Marrow versus Conventional Bone Marrow as a Stem Cell Source In
Matched Sibling Donor Transplantation
BMT CTN 0601: Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced-Intensity Conditioning
Regimen.
PBMTC NMD0901: A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Thalassemia Using a Reduced-Intensity
Conditioning Regimen, with the Thalassemia Trials Network
BMT indicates bone marrow transplant; PBMTC, Pediatric Blood and Marrow Transplant Consortium; COG, Children’s Oncology Group; BMT CTN,
The Blood and Marrow Transplant Clinical Trials Network; ASCT, allogeneic stem cell transplant.
Biol Blood Marrow Transplant 16:1212-1221, 2010 1213Priorities of the Pediatric Blood and Marrow Transplant Consortiuma handful of transplantations each year for any specific
indication. The fact that meaningful clinical research
requires collaborative, multi-institutional studies with
a large number of relatively small centers is becom-
ing increasingly apparent.
Over the past few years, efforts by 3 large cooper-
ative groups in North America and Australia—the
Children’s Oncology Group (COG), the Blood and
Marrow Transplant Clinical Trials Network (BMT
CTN) and the Pediatric Blood and Marrow Trans-
plant Consortium (PBMTC)—have resulted in the
planning and implementation of a series of multicenter
pediatric transplantation trials (Table 1). The COG
conducts cancer-related BMT trials in children, and
the BMTCTNconducts adult and pediatric multicen-
ter trials addressing all aspects of the transplantation
experience. Both groups focus on large phase II and
III trials. The BMT CTN is committed to developing
selected larger trials in malignant and nonmalignant
pediatric conditions and is currently conducting
a phase II trial evaluating transplantation in children
with sickle cell disease; however, its commitment to
larger trials means that ideas requiring small pilot
studies generally are not considered in its scientific
agenda. Pilot data are needed when considering larger
trials, but these data are lacking for many issues related
to pediatric BMT, including transplantation strategies
for both malignant and nonmalignant disorders.
Comprising 77 full-member pediatric centers in
North America, Australia, and New Zealand, the
PBMTC is the largest clinical trials group focused ex-
clusively on BMT in children and adolescents. The
PBMTC works closely with both the COG and the
BMT CTN. Most PBMTC centers participate in
COG trials, and many PBMTC investigators are in-
volved in COG Hematopoietic Stem Cell Transplan-
tation (HSCT) Committee leadership and COG study
development. This facilitates transition of successful
PBMTC pilot trials focused on cancer into larger
COG trials. The BMT CTN comprises 16 core cen-
ters, 13 of which are large transplantation centers
with both adult and pediatric programs, 2 of which
are small consortia, and the remaining core center is
the PBMTC. As mentioned earlier, pediatric trans-
plantation indications are rare, and including thePBMTC as a core center of the BMT CTN provides
the opportunity to participate in BMT CTN studies
for more than 60 additional pediatric centers who are
not part of other core centers. This is important, be-
cause successful pediatric HSCT trials often require
at least 30-40 centers because of the rarity of the dis-
eases for which transplantation is performed. Because
the PBMTC is a core center, the PBMTC chair sits
on the BMT CTN steering committee, and PBMTC
leadership participate in BMT CTN committees and
leadership. In addition, PBMTC members can
propose trials for consideration by the BMT CTN
steering committee.
As alluded to earlier, the PBMTC has assumed
a role in developing novel, early-phase trials that can
provide necessary preliminary data for larger COG
and BMT CTN trials. The PBMTC is the only large
cooperative group committed to studying many rare
conditions in which phase III trials are not possible.
BMT to treat these orphan diseases can be advanced
only by smaller studies performed by a large group,
such as the PBMTC. The PBMTC has developed
the necessary infrastructure to develop both pilot stud-
ies and broad-based trials addressing the treatment of
rare orphan diseases by BMT with a grant from the
St Baldrick’s Foundation, a charitable organization
dedicated to fighting childhood cancer. A formal col-
laboration agreement was established in 2009 between
the PBMTC and the clinical trial arm of the Center for
International Blood and Marrow Transplant Research
(CIBMTR), the Resource for Clinical Investigations in
Blood and Marrow Transplantation (RCI-BMT).
This collaboration included development of a high-
quality, good clinical practice–compliant clinical
trials infrastructure that uses the data and trials
management resources and expertise of the CIBMTR.
Both the PBMTC and the CIBMTR perform
studies involving centers in countries worldwide.
The PBMTC operations center is part of the National
Children’s Cancer Foundation (the charitable arm and
financial operations center of the COG). This organi-
zation performs contracts with COG-affiliated centers
around the world, and this expertise is used by the
PBMTC. The long-standing PBMTC membership
of transplantation groups from Canada, Australia,
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for institutional ethics board review and data quality
assurance. The CIBMTR/National Marrow Donor
Program (NMDP) has established contractual rela-
tionships with PBMTC centers inside and outside
the United States, simplifying data-transfer arrange-
ments. Trials proposed by members are developed
and prioritized through a subcommittee structure
(see later). Developed protocols undergo review
through the PBMTC Scientific Review Committee,
with a nonbinding review by the RCI-BMT’s Scien-
tific Advisory Committee. Final study approval is pro-
vided through a vote of the PBMTC Executive
Committee, a body elected by PBMTC members.
Studies are funded by the St Baldrick’s Foundation, in-
dividual governmental and nongovernmental research
grants, and industry sponsorship.
In April 2009, A PBMTC strategic planning meet-
ingwasheld inVancouver,Canada, that included senior
PBMTC and COG transplantation leadership and
chairs and vice-chairs of PBMTC subcommittees in
nonmalignant disorders, oncologic disorders, stem
cell sources/cellular therapeutics, graft-versus-host dis-
ease (GVHD), and supportive care. In addition, repre-
sentatives from the RCI BMT, the National Heart,
Lung, andBlood Institute (NHLBI), theNationalCan-
cer Institute (NCI), the National Institute of Allergy
and Infectious Diseases (NIAID), and the St Baldrick’s
Foundation participated in the discussions, with each
group sharing its research agenda.Themeeting focused
on defining knowledge gaps and study opportunities in
the 5 broad strategy areasmentioned earlier. Themeet-
ing concluded with the development of research
priorities along with strategies for infrastructure devel-
opment and funding for pediatric BMT. Priorities in
the 5 areas addressed by PBMTC subcommittees are




Nonmalignant diseases treated by BMT represent
a wide array of diverse disorders, and include approxi-
mately 35% of pediatric patients undergoing BMT at
PBMTC member institutions. Recognizing that each
of these disorders is rare, PBMTC investigators seek
to develop feasible national protocols, using the accrual
power of the consortium, to address the most pressing
clinical questions that may improve the treatment of
childrenwith these disorders. Although somedisorders
involve unique issues that are most effectively ad-
dressed by disease-specific protocols, others share
common challenges allowing for multi-disease proto-
cols. The PBMTC has developed collaborations withestablished disease-specific networks when possible
and initiated trials to fill unmet needs. Five major cate-
gories of nonmalignant disorders are treatable by
BMT: (1) hemoglobinopathies, (2) immune deficiency
and dysregulation disorders, (3) metabolic storage
diseases, (4) BM failure syndromes, and (5) a group of
individually unique disorders, such as the leukodystro-
phies and osteopetrosis. Novel indications for BMT,
such as autoimmune illness, and the use of other cellu-
lar therapeutic approaches to treat these and other dis-
eases are also part of the nonmalignant disorders group.
What are the pressing clinical challenges in BMT
for nonmalignant disorders? First, although matched
sibling transplantation using myeloablative (MA) ap-
proaches is well established for many nonmalignant
disorders, treatment-related mortality (TRM) and
GVHD-associated morbidity remains high with unre-
lated donor (URD) BMT [1,2]. Reduced-intensity
conditioning (RIC) regimens hold the promise of de-
creasing TRM in these disorders, but graft rejection
has limited the widespread application of this approach
[3]. PBMTC investigators have developed a novel RIC
approach that has been adopted by the BMT CTN as
a URD transplantation protocol for sickle cell anemia
(BMTCTN 0601; Tables 1 and 2) [4]. In addition, the
PBMTC has launched a similar trial for thalassemia in
cooperation with the Thalassemia Clinical Research
Network (TCRN-PBMTC NMD091). PBMTC in-
vestigators are collaborating with the BMT CTN to
develop a trial of a novel RIC transplantation regimen
to treat the immune regulation disorder hemophago-
cytic lymphohistiocytosis. Continuing efforts to de-
velop regimens that ensure engraftment in
nonmalignant disorders while limiting TRM and
GVHD will remain a top priority over the next several
years.
A second major clinical challenge in nonmalignant
BMT is the lack of understanding of outcomes and
a consensus approach to BMT for immunodeficiency
disorders, especially severe combined immune defi-
ciency (SCID) [5]. In the past, most transplantations
for these disorders were done at a limited number of
large centers. Today, however, a large number of
smaller centers are performing BMT in these children.
Because of the ability to engraft T cells with minimal
preparation in many of these children, approaches
vary dramatically, ranging from simple infusions of
T cell–depleted maternal haploidentical grafts without
a preparatory regimen to MA approaches for all pa-
tients [6]. The PBMTC is working cooperatively as
a participant in the Primary Immune Deficiency
Treatment Consortium (PIDTC), which recently
was awarded an NIAID/Office of Rare Diseases
(ORD) U54 grant to study survival and immunologic
outcomes, both retrospectively and prospectively, in
these patients. PBMTC investigators feel that a key
initiative in the coming years will be to design
Table 2. Hypotheses and Study Priorities in BMT for Nonmalignant Pediatric Disorders
Disease Hypotheses Current Study/Strategy
Hemoglobinopathies: Expand donor pool to URD BMT CTN 0601
Sickle cell disease, thalassemia Reduced intensity 5 less TRM, late effects PBMTC NMD0901
Hemophagocytic lymphohistiocytosis Decreased inflammatory response, less TRM with
reduced-intensity regimen
PBMTC joint with BMT CTN committee: U34
submitted
Immune deficiencies
SCID Long-term outcomes of current approaches unknown Outcomes: retrospective and prospective through
PIDTC U54
SCID Achievement of B cell and T cell with high stem cell/dose
plus reduced-intensity regimen
PBMTC study committee/planned grant effort
Metabolic storage diseases Neurocognitive outcomes differ with disease/stem cell
source/age; standardization of outcome measures is
needed
PBMTC/Hunter’s Hope/Lysosomal Disease Network
U54 grant joint effort
Bone marrow failure
SAA Decrease rejection of cord blood; expand donor pool PBMTC study committee/grant submitted
BMT indicates bone marrow transplant; PBMTC, Pediatric Blood and Marrow Transplant Consortium; COG, Children’s Oncology Group; BMT CTN,
The Blood and Marrow Transplant Clinical Trials Network; TRM, treatment related mortality; SCID, severe combined immune deficiency; PIDTC, Pri-
mary Immune Deficiency Treatment Consortium; URD, unrelated donor, SAA, severe aplastic anemia.
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PIDTC, with a primary aim of establishing both T
cell and B cell immune competence using both related
donor and URD stem cell sources.
A PBMTC protocol team is working with the
Hunter’s Hope Foundation and a U54-funded team
from the Lysosomal Disease Network (LDN) to de-
velop (1) an initiative aiming to standardize evaluation
of the neurocognitive outcomes of children who have
previously undergone BMT, and (2) a prospective
therapeutic transplantation study for selected meta-
bolic disorders. A key opportunity for studying BMT
for metabolic storage diseases is provided by newborn
screening for these diseases in several states [7]. Iden-
tification of younger high-risk children with some of
these diseases may allow BMT at an earlier time point,
limiting neurologic damage and possibly improving
outcomes. Questions regarding the impact of geno-
type/phenotype analysis of specific mutations will
assist in identifying individuals with severe or milder
phenotypes, guiding the use of BMT versus enzyme-
replacement strategies.
Finally, although umbilical cord blood (UCB)
transplantation is done routinely for many malignant
and nonmalignant disorders, high rates of rejection
and TRM have limited the use of this stem cell source
for BMT in children with severe aplastic anemia (SAA)
who have failed immunosuppressive therapy [8]. Re-
cent data generated by PBMTC investigators provide
the basis for a current initiative to develop an innova-
tive RIC approach to allow the use of UCB in this pop-
ulation [9]. To date, BMT has been most effective in
this group only when a fully HLA-matched URD is
available (approximately 30%-40% of the time). Be-
cause UCB BMT can succeed with less-stringent
HLA matching, improving UCB outcomes in SAA
could allowmore than 90% of children with this disor-
der who fail immunosuppression a chance at curative
therapy.In summary, PBMTC initiatives to improve out-
comes after BMT for nonmalignant disorders include
targeted efforts to (1) establish long-term engraftment
of URD sources using safer reduced-intensity ap-
proaches, (2) ensure T cell and B cell engraftment
and functional immunity after BMT in patients with
SCID, (3) standardize assessment of and learn more
about neurologic outcomes after transplantation of
selected metabolic storage diseases to establish the
timing and appropriateness of BMT, and (4) establish
approaches that result in high rates of engraftment and
survival using UCB for patients with SAA who have
failed immunosuppressive therapy (Table 2).BLOODAND MARROW TRANSPLANTATION
FOR PEDIATRIC MALIGNANT DISORDERS
Approximately 65%-70% of BMTs in children are
performed for high-risk malignancies. MA approaches
to BMT deliver maximal treatment intensity and allo-
geneic BMT approaches deliver immunotherapy
through a graft-versus-malignancy effect. But, despite
this intense approach, relapse remains the major cause
of death in children undergoing BMT for malignancy.
With that inmind, themajor focus of the PBMTCOn-
cology StrategyGroup is prevention of relapse.Under-
standing the mechanisms of relapse after BMT is
critical for designing more effective and selective
BMT therapy. Relapse after BMT implies the
existence of mechanisms of chemoresistance, radiore-
sistance, and immunoresistance. The presence of
detectable minimal residual disease at the time of the
pretransplantation workup is associated with an in-
creased risk of relapse [10,11]. Possible mechanisms
to explain this observation include a threshold effect,
with an unfavorable effector-to-target ratio; a dose
phenomenon that alters the immunologic response;
active induction of tolerance by malignant cells;
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lack of immunogenicity in malignant cells; loss of tar-
get antigens by malignant cells; exhaustion of effector
clones; or inadequate T cell function against malignant
clones.
Two strategies to reduce the risk of relapse after
allogeneic BMT are to administer agents that increase
cancer cell susceptibility to immune approaches (ie, in-
duction of apoptosis) and to increase the effectiveness
of the BMT in treating the malignant clone. One way
to affect cancer cell susceptibility is to administer
mTOR inhibitors, such as sirolimus, which induce ap-
optosis. Sirolimus has both antitumor and immuno-
suppressive properties and is currently being studied
in a phase III COG/PBMTC study (ASCT0431/
PBMTCONC051), with a hypothesis that its antileu-
kemic and proapoptotic effect will decrease relapse
posttransplantation for children with acute lympho-
blastic leukemia (ALL) [12]. Targeted therapies with
side effect profiles compatible with posttransplanta-
tion administration, such as tyrosine kinase inhibitors
(TKIs; eg, imatinib mesylate), may take minimal resid-
ual disease below an immunologic threshold post-
transplantation, reducing relapse. In addition, TKIs
have been shown to have a number of immunologic ef-
fects, working synergistically with donor lymphocyte
infusions [13]. A top priority of the oncology strategy
group will be further testing of targeted agents and im-
munotherapeutic strategies (see Cellular Therapeu-
tics) to prevent relapse in the very-high-risk patients
undergoing allogeneic and autologous BMT. In addi-
tion, whereas the role of BMT as active immunother-
apy is well established in hematologic malignancies,
the role of alloimmunity in treating chemorefractory
pediatric solid tumors is currently being explored. Ef-
forts to improve the efficacy of BMT or immunother-
apeutic approaches to refractory solid tumors merit
continued attention.
Finally, an important issue after BMT in growing,
developing children is the challenge of late effects,
including infertility, endocrine issues, and second
malignancies. The PBMTC has made significant con-
tributions to defining the role of RIC transplantation
in pediatric hematologic malignancies [12]. Continued
efforts to define novel approaches to reduce toxicity
and decrease late effects, while preserving anticancer
efficacy, will remain a priority.
In summary, future efforts to improve outcomes
after BMT for malignant disorders should focus on
prevention of relapse through (1) manipulation or en-
hancement of alloimmunity after transplantation, (2)
use of peritransplantation cellular therapy or immuno-
therapy, and (3) use of relevant molecularly targeted
therapies that can be administered in the peritrans-
plantation period. In addition, further exploration of
the appropriate role of RIC approaches for pediatric
malignancies is warranted.STEM CELL SOURCES AND CELLULAR
THERAPEUTICAPPROACHES IN PEDIATRICS
An ideal stem cell source provides earlymyeloid and
lymphoid engraftment without excessive GVHD. To
achieve this goal, the PBMTC conducted a pilot trial
using granulocyte colony-stimulating factor (G-CSF)-
primed BM for children undergoing transplantation
from related donors [14]. The graft content of G-CSF–
primed BM included high doses of CD341 cells
with low CD31 doses compared with peripheral blood
stem cells, resulting in rapid engraftment and low rates
of chronicGVHD (cGVHD). The study provided pre-
liminary data for an ongoing, jointly developed
(PBMTC/COG) phase III trial running through the
COG (ASCT0631; Table 1). An important question
in alternative donor sources is how the use of 1 or
2 UCB units affects transplantation outcomes. The
PBMTC is participating in BMT CTN 0501, a study
of single UCB versus double UCB transplantation in
pediatric malignancies, testing whether or not a second
cord leads to less relapse because of added immunoge-
nicity. These studies will add to a large body of work
compiled over the past decade that has defined high-
quality stem cell sources for the large majority of
patients requiring BMT.
To further improve outcomes using these stem cell
sources, the next generation of studies in this area will
involvemanipulation cells within a graft to improve en-
graftment, decrease GVHD, or enhance the antima-
lignancy effect. Although all forms of BMT are
‘‘cellular therapy,’’ our use of the term includes manip-
ulations and enhancement of grafts or generation of
cellular products from nongraft sources. There are 2
broad approaches to performing cellular therapy in
the context of BMT [15]. One approach involves using
autologous cells that have been manipulated to better
target the patient’s cancer and strengthen the patient’s
immune response. A tumor has escaped the body’s im-
mune surveillance, and overcoming this immunologic
resistance can be challenging; however, autologous
cells can live longer and can maintain immune surveil-
lance if stimulated appropriately, and thus they carry
a lower risk of untoward reactions, such as GVHD. A
second approach involves using allogeneic cells, which
have the capacity for more potent antitumor activity.
Modified allogeneic cells can be used before transplan-
tation to increase the depth of a remission, or as part of
the BMT or posttransplantation to decrease the risk of
relapse or GVHD. Although immunoresistance is the
primary challenge in the application of autologous
cells, alloimmune-mediated morbidity (eg, GVHD,
organ damage) will remain a challenge with the use of
allogeneic approaches.
PBMTC centers are pursuing various immuno-
logic and cellular therapeutic approaches to decrease
relapse. The infusion of antigen-specific T cells in
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immunotherapy offers an approach to treating malig-
nancies that may avoid the long-term toxicities associ-
ated with conventional cytotoxic chemotherapy and
radiation therapy. Current studies on reconstituting
or augmenting cellular immunity through the infusion
of T cells are limited to single-center or small group
studies because of a number of barriers [16].
The major challenges in pursuing adoptive cellular
therapies in children are the current lack of significant
funding for such trials and the daunting regulatory bur-
den associated with conceiving and executing such ther-
apies in a multicenter setting. The PBMTC cellular
therapy strategy group is committed to evaluating cellu-
lar therapies in amulticenter setting. Themost pressing
initial challenge is to establish the regulatory infrastruc-
turewithin the PBMTCnecessary to conduct andmon-
itor such multicenter trials. The feasibility and safety of
shipping cells between centers and incorporating such
therapies with current therapies must be studied, and is-
sues regarding limiting indemnification of the sponsor-
ing institution must be resolved. We believe that
important advances in curing high-risk malignant dis-
eases will involve directed adoptive cellular therapies.
In summary, PBMTC efforts in cellular therapy
will start with the testing of promising approaches in
a limited-center setting. Once feasibility is established,
we will expand these cellular approaches into larger
multicenter studies.KEY ISSUES IN PEDIATRIC GVHD
Young children differ from others in their rate of
GVHD and their ability to recover from GVHD,
likely because of thymic activity in the first decades
of life. Differences in drug metabolism and the chal-
lenges of administering some GVHD therapies to
younger children add to the complexity. Only studies
that take these distinct differences in young children
into account will be able to define optimal GVHD
therapy for this group [17].
GVHD remains the major complication of alloge-
neic BMT. Approaches to improving treatment have
focused on biomarkers that can predict the develop-
ment of GVHD or provide a better understanding of
which therapies work best. The PBMTC has assessed
both mechanisms and biomarkers associated with the
development of GVHD and tested novel therapies
for acute GVHD (aGVHD) and cGVHD. Approaches
that augment treatment in all patients diagnosed with
aGVHD can lead to overtreatment of some patients
and worse outcomes because of increased relapse,
along with infectious mortality [18]. Thus, identifica-
tion of patients at high risk for developing aGVHD
could lead to individualized treatment approaches
based on the risk for GVHD. The PBMTC conducteda study of cytokine gene polymorphisms in 185 chil-
dren undergoing 6/6 matched URD transplantations
at 28 institutions. A significant relationship was ob-
served between tumor necrosis factor-a genotypes
and haplotype and the risk of aGVHD [19]. We are
currently evaluating the relationship between other
gene polymorphisms and posttransplantation out-
comes. A major goal of the PBMTC over the next
few years will be to prospectively validate multiple bio-
markers (eg, proteomic, RNA-based studies of genetic
alterations before GVHD) in the pediatric HSCT set-
ting. These results, combined with our cytokine poly-
morphism study outcomes, will result in identification
of patients who are at high risk for GVHD and thus
may benefit from augmented immunosuppression.
The PBMTC recently completed accrual of 51
children from 24 institutions onto a phase II study
evaluating the safety and efficacy of pentostatin in re-
fractory cGVHD. The drug was well tolerated, and
the overall response was 53% [20]. A small group of
PBMTC centers will conduct a limited-institution
phase I study to examine the toxicity of the CellEx
photopheresis machine in children with refractory
cGVHD. This study will explore the feasibility of ex-
tracorporeal photochemotherapy apheresis in very
young children using newer-generation machines bet-
ter able to serve ‘‘small-volume’’ young children.
In summary, future GVHD studies should focus
on validating biomarkers and performing trials of spe-
cific agents and approaches that will help us better un-
derstand and respond to the unique therapeutic needs
and immunologic and physiological differences of
young children.SUPPORTIVE CARE CHALLENGES IN
PEDIATRIC BMT
Supportive care practices comprise a panoply of
medical interventions aimed at improving the outcome
of BMT. Over the past 2 decades, improvements in
supportive care have been a key factor in the significant
decrease in TRM associated with both autologous and
allogeneic BMT.Of note, although outcomes have im-
proved, centers vary widely in their use of supportive
care practices, such as antibacterial prophylaxis or
treatment, antifungal prophylaxis and treatment, viral
monitoring, nutritional support, and menstrual sup-
pression. Well-designed trials may contribute to the
standardization and improvement of supportive care
practices. Two pertinent examples from the PBMTC
supportive care group include a phase III study dem-
onstrating the utility of oral glutamine in preventing
mucositis [21] and a recently completed phase I trial
of palifermin in children.
We consider 2 areas of supportive care to be of
high priority in children. First, the use of total body
Table 3. PBMTC Key Priorities for Pediatric BMT
1. Develop preparative approaches using URD grafts that offer long-term engraftment, reduced toxicity, and reduced GVHD for nonmalignant disorders.
2. Develop safer approaches to BMT for patients with SCID that allow consistent establishment of long-term, functional B cell and T cell immunity using related
and URD sources.
3. Study neurocognitive outcomes after BMT for metabolic storage diseases, and develop prospective trials aimed at improving the safety and efficacy of BMT in
this population.
4. Develop approaches that allow high levels of successful engraftment in patients with SAA failing immune suppression using unrelated cord blood.
5. Decrease relapse after BMT for malignant disorders by (1) manipulation or enhancement of alloimmunity, (2) use of peritransplantation cellular therapy, or (3)
use of peritransplantation targeted therapies.
6. Further explore the appropriate role of reduced-intensity approaches for selected pediatric malignancies.
7. Pilot-test promising cellular therapy approaches in a limited-center setting, followed by expansion into larger multicenter studies. This includes overcoming
infrastructure, regulatory, investigational new drug (IND) issues, and funding challenges.
8. Validate biomarkers in and perform GVHD trials targeted at the specific needs of young children.
9. Study the neurocognitive impact of TBI and other myeloablative approaches in infants and younger children.
10. Study the significance and impact of new therapies, and therapeutic outcomes of infection with selected viral pathogens in children.
PBMTC indicates Pediatric Blood and Marrow Transplant Consortium; BMT, bone marrow transplant; URD, unrelated donor, SAA, severe aplastic ane-
mia; SCID, severe combined immune deficiency; GVHD, graft-versus-host disease; TBI, total body irradiation.
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considerable debate. There are concerns about the
long-term neurocognitive and neuroendocrine se-
quelae of TBI in children under 2 or 3 years of age.
PBMTC data since 2000 reflect marked variations in
practice by center: 46% of reported patients with
ALL under age 2 years received TBI, with the remain-
ing institutions using a variety of other approaches.
There is a paucity of information on this subject, be-
cause few studies have targeted this population.
Sanders et al. [22] reported that 15 infants who re-
ceived 13.2-15.75 cGy TBI had a mean full-scale IQ
of was 104 6 14 at a median age of 4.4 years. Phipps
et al. [23], however, described declining IQ scores at
1 and 3 years posttransplantation in children who
underwent transplantation before 3 years of age,
although the number of patients in this age group
was insufficient to determine whether TBI had
a greater impact than non-TBI regimens. These find-
ings were called into question in a subsequent report
by the same group [24]. Because TBI-based regimens
offer a survival benefit for older recipients with high-
risk ALL [25], understanding the developmental im-
plications of this therapy on infants is important.
The PBMTC will seek funding to address this issue
by studying very young patients in the PBMTC data-
base who underwent transplantation with and without
TBI, comparing their neurocognitive and functional
outcomes. This study also will address the neurocogni-
tive implications of other transplantation preparative
agents, such as busulfan, commonly used in this popu-
lation and known to have long-term implications in
pediatric transplantation survivors [26].
Another area of special concern in pediatrics is the
treatment of opportunistic viral pathogens. The fre-
quent use of cord blood (a relatively T cell–depleted
product with slower immune recovery), transplanta-
tion in children with inherited immune deficiencies
(often starting BMT with active viral infections), and
transplantation in infants (immature immune systems)
lead to unique infectious complications that warrant
specific study. Whereas cytomegalovirus has beenwidely investigated, approaches to very young children
with infections resulting from other pathogens, such as
adenovirus, BK virus, and human herpesvirus-6
(HHV-6), require further study. Reports have demon-
strated a mortality of 50% (27%-65%) from invasive
adenovirus after allogeneic BMT [27,28]. More recent
reports have shown improved outcomes using strate-
gies that combine close monitoring for adenovirus
with either preemptive or therapeutic cidofovir
[29,30]. The use of cidofovir is limited by nephrotocix-
ity, however, leaving patients with no other proven
therapeutic options. New compounds, such as
CMX001, a lipid-ester derivative of cidofovir, may
be available for study in the near future [31]. Under-
standing the significance of BK and HHV-6 detection
and infection, as well as the risks and benefits of ther-
apy of these infections, also requires further study. The
PBMTC, in partnership with industry and viral study
groups, is committed to developing approaches to bet-
ter understanding and treating these infections in the
pediatric BMT setting.
In summary, PBMTC efforts in supportive care
studies will focus on understanding the developmental
impact of TBI and other types of intense preparative
regimens in infants and younger children, and on
understanding and treating unusual viral infections
relatively common in pediatric BMT, including
adenovirus, BK virus, and HHV-6.CONCLUSION
Advancement in several key areas of pediatric
BMT will be strengthened by the newly formed part-
nership between the PBMTC and the CIBMTR/
NMDP (RCI-BMT). This partnership will facilitate
the accomplishment of important pediatric BMT pri-
orities (Table 3). Close working relationships among
the BMT CTN, the COG, and the PBMTC have
been established and are vital in developing early-
phase trials and then transitioning them to large phase
II and III trials. Cooperation with disease-specific
Biol Blood Marrow Transplant 16:1212-1221, 2010 1219Priorities of the Pediatric Blood and Marrow Transplant Consortiumgroups, such as the Thalassemia Clinical Trials Net-
work, the PIDTC and the LDN will further facilitate
trial development. Finally, it it important to emphasize
that the field will only move forward as governmental
and non-governmental organizations recognize the
unique aspects of pediatric BMT and fund trials that
address the critical needs of this population.ACKNOWLEDGMENTS
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PBMTC Full Member Institutions
Alberta Children’s Hospital, Calgary Alberta,
Canada
All Children’s Hospital, St Petersburg, Florida
The Floating Hospital for Children at Tufts Med-
ical Center, Boston, Massachusetts
British Columbia Children’s Hospital, Vancouver,
British Columbia, Canada
CancerCare Manitoba, Winnipeg, Manitoba,
Canada
Children’s Healthcare of Atlanta at Egleston,
Atlanta, Georgia
Seattle Children’s / Fred Hutchinson Cancer
Center, Seattle, Washington
Children’s Hospital Oakland, Oakland, California
Children’s Hospital of Los Angeles, Los Angeles,
California
Children’s Hospital of Michigan, Detroit,
Michigan
Children’s Hospital of Orange County, Orange,
California
Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania
Children’s Hospital of Pittsburgh, Pittsburgh,
Pennsylvania
Children’s Memorial Medical Center at Chicago,
Chicago, Illinois
Children’s National Medical Center,Washington,
DC
Children’s Hospital of NewOrleans/LSUMedical
Center, New Orleans, Louisiana
Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio
Cook Children’s Hematology & Oncology
Center, Fort Worth, Texas
Dana-Farber Cancer Institute, Boston, Massachu-
setts
DoernbecherChildren’sHospital/OregonHealth&
Sciences University, Portland, Oregon
Duke University Medical Center, Durham, North
Carolina
Hackensack University Medical Center, Hacken-
sack, New Jersey
CHU Sainte-Justine, Montreal, Quebec, Canada
Johns Hopkins Hospital, Baltimore, Maryland
Kosair Children’s Hospital, Louisville, Kentucky




Mayo Clinic, Rochester, Minnesota
M.D. Anderson Cancer Center, Houston, Texas
Medical University of South Carolina, Charleston,
South CarolinaMethodist Children’s Hospital of South Texas,
San Antonio, Texas
Miami Children’s Hospital, Miami, Florida
Midwest Children’s Cancer Center / Medical
College of Wisconsin, Milwaukee, Wisconsin
Mount Sinai School of Medicine, New York, New
York
Nationwide Children’s Hospital, Columbus,
Ohio
Nemours Children’s Clinic, Jacksonville, Florida
New York Medical College, Valhalla, New York
New York University Medical Center, New York,
New York
Penn StateUniversity -Milton S.HersheyMedical
Center, Hershey, Pennsylvania
Phoenix Children’s Hospital, Phoenix, Arizona
Rady Children’s Hospital San Diego, San Diego,
California
Rainbow Babies & Children’s Hospital / Case
Western Reserve University, Cleveland, Ohio
Riley Hospital for Children, Indiana University,
Indianapolis, Indiana
Roswell Park Cancer Institute, Buffalo, New York
Schneider Children’s Hospital, New Hyde Park,
New York
St Jude Children’s Research Hospital, Memphis,
Tennessee
Stanford University School of Medicine, Stanford,
California
Texas Children’s Cancer Center at Baylor College
of Medicine, Houston, Texas
The Children’s Hospital of Denver, Denver,
Colorado
The Children’s Mercy Hospital, Kansas City,
Missouri
The Hospital for Sick Children, Toronto,
Ontario, Canada
The Morgan Stanley Children’s Hospital of New
York – Presbyterian, New York, New York




University of Alabama at Birmingham, Birming-
ham, Alabama
University of Arizona Health Sciences Center,
Tucson, Arizona
University of California Davis School ofMedicine,
Sacramento, California
University of California San Francisco School of
Medicine, San Francisco, California University of
Florida, Gainesville, Florida
University of Iowa Hospitals & Clinics, Iowa City,
Iowa
University of Miami Jackson Memorial Hospital,
Miami, Florida
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Children’s Hospital, Ann Arbor, Michigan
University ofMinnesota Cancer Center,Minneap-
olis, Minneapolis
University of Mississippi Medical Center, Jackson,
Mississippi
University of Nebraska Medical Center, Omaha,
Nebraska
University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina
University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma
University of Rochester Medical Center,
Rochester, New York
University of UtahMedical Center / PrimaryChil-
dren’s Medical Center, Salt Lake City, Utah
University of Wisconsin Children’s Hospital,
Madison, Wisconsin
University of Texas SouthwesternMedical Center /
Children’s Medical Center, Dallas, Texas
Vanderbilt University Medical Center, Nashville,
Tennessee
Virginia Common Wealth University Health Sys-
tem, Richmond, Virginia
Washington University-St. Louis Children’s Hos-
pital, St Louis, Missouri
Princess Margaret Hospital for Children, Perth,
Western Australia, Australia
Royal Children’s Hospital, Brisbane, Brisbane,
Queensland, Australia
Starship Children’s Hospital, Auckland, New
Zealand
The Children’s Hospital at Westmead,
Westmead, New South Wales, AustraliaPBMTC Associate Member Institutions
Cancer Institute of New Jersey, New Brunswick,
New Jersey
Cardinal Glennon Children’s Medical Center-
Saint Louis University, St Louis, Missouri
Children’s Hospital of Central California,Madera,
CaliforniaChildren’s Hospital Medical Center of Akron,
Akron, Ohio
Children’s Hospital of Montefiore, Bronx, New
York
Children’s Hospitals and Clinics of Minnesota,
Minneapolis, Minnesota
DeVos Children’s Hospital, Grand Rapids,
Michigan
Florida Hospital Cancer Institute, Orlando,
Florida
Maine Children’s Cancer Program, Scarborough,
Maine
McGill University Health Center - Montreal
Children’s Hospital, Montreal, Quebec, Canada
Medical College of Georgia, Augusta, Georgia
National Cancer Institute, Bethesda, Maryland
St Christopher’s Hospital for Children, Philadel-
phia, Pennsylvania
Stollery Children’s Hospital, Edmonton, Alberta,
Canada
Tulane University/Tulane University Hospital &
Clinic, New Orleans, Louisiana
University of Hawaii/Kapiolani Med Center for
Women & Children, Honolulu, Hawaii
University of Arkansas for Medical Sciences, Little
Rock, Arkansas
University of Kentucky Markey Cancer Center /
A.B Chandler Medical Center, Lexington, Kentucky
Yale University School of Medicine, New Haven,
Connecticut
Colombian Childhood Cancer Parents Organiza-
tion, Bogota, DC, Colombia
Hospital de Clinicas de Porto Alegre, Porto
Alegre, RS, Brazil
Instituto deOncologia Pediatrica, SaoPaulo, Brazil
Ramathibodi Hospital, Bangkok, Thailand
Royal Children’s Hospital, University of
Melbourne, Parkville, Victoria, Australia
Sydney Children’s Hospital, Sydney, New South
Wales, Australia
University Hospital Brno, Brno, Czech Republic
Women & Children’s Hospital, Adelaide, North
Adelaide, South Australia, Australia
